Related Experiment Video
Updated: May 8, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
[Antithrombotic treatment and cancer]
Guy Meyer1, Olivier Sanchez, Benjamin Planquette
1Université Paris Descartes, Sorbonne Paris Cité, AP-HP, hôpital européen Georges-Pompidou, service de pneumologie et soins intensifs, Inserm UMR S 970, 20, rue Leblanc, 75015 Paris, France.
Abstract:
Five to 10 % of cancers are complicated by venous thromboembolism. A score is available to classify patients according to their risk of venous thromboembolism. The long-term prophylaxis is not recommended in patients with cancer, even if it reduces the incidence of thromboembolic events, due to the high number of patients to treat to prevent one event. The treatment of venous thromboembolism in cancer is based on the use of low-molecular weight heparin for at least 3 months. The potential role of antithrombotic drugs in the prevention and adjuvant treatment of some cancers is being evaluated.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...